Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Category Archives: News

06Jan/24

A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection

January 6, 2024News, Recombinant Antibody R&DInfluenza Virus, Neutralizing Antibodybiorab

The titers of antibodies that inhibit the receptor binding of hemagglutinin (HA), a key viral protein of the influenza virus, are widely recognized as directly related to protecting organisms against infection. Recently,Read More…

04Dec/23

Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections

December 4, 2023News, Therapeutic Antibody R&DNeutralizing Antibody, Pseudomonas aeruginosabiorab

Pseudomonas aeruginosa possesses multiple mechanisms of antibiotic resistance, leading to high morbidity and mortality rates. It may result in complex infections and dangerous septic cases in critically ill patients. In a recentRead More…

02Sep/23

Controlling Widespread Neutralizing Antibodies Produced in Post-Treatment Controllers Promotes Long-Term Remission of HIV-1 Infection

September 2, 2023News, Therapeutic Antibody R&DHIV-1 Infection, Neutralizing Antibodiesbiorab

Some HIV-1 carriers who received early antiretroviral therapy (ART) for several years can maintain long-term control over the virus after treatment interruption. However, the mechanism behind this post-treatment control is not fullyRead More…

12May/23
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Targeting PD-L2-RGMb Promises to Enhance the Efficacy of Cancer Immunotherapy

May 12, 2023News, Therapeutic Antibody R&DCancer Immunotherapy, Targeting PD-L2-RGMbbiorab

Immunotherapy has revolutionized the treatment of many cancer types. However, for reasons that remain poorly understood, not all patients respond equally from these potent therapies. In a recent study, researchers from HarvardRead More…

30Apr/23
Recombinant Antibody

Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors

April 30, 2023Cancer Immunotherapy, NewsGastrointestinal Tumor, immunotherapybiorab

The morbidity and mortality of intestinal tumors are among the top malignant tumors, and they are major diseases that seriously threaten people’s health. The prognosis for some patients with gastrointestinal malignancies hasRead More…

12Mar/23

Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations

March 12, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Neoantigens are peptides derived from nonsynonymous mutations in human leukocyte antigens (HLAs) that are recognized by antitumor T cells. The large diversity of HLA alleles and limited clinical samples often narrow scientists’Read More…

02Jan/23

Scientists Discovered the Key Molecule Triggering Cancer Metastasis

January 2, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Many cancer cells never leave their original tumor tissue. Some cancer cells have evolved the ability to migrate to other tissues, but they will become dormant once they are unable to formRead More…

05Dec/22

Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis

December 5, 2022Cancer Immunotherapy, NewsCancer Immunotherapybiorab

The paradigm of the adenoma-cancer sequence has typically focused on cancer cells in colorectal cancer (CRC) development that is already validated to entail heterologous interactions between altered cells and their surrounding microenvironment.Read More…

23Sep/22

Creative Biolabs Attended the 13th World Bispecific Summit as An Exhibition Partner

September 23, 2022NewsBispecific Antibody, World Bispecific Summitbiorab

As multispecifics is hailed the fourth wave of drug discovery, with more clinical candidates and commercial success than ever before, the 13th World Bispecific Summit arrived at a pivotal time to deliver the holyRead More…

05Apr/20

Alternatives to Cope with Lengthy Clinical Development Process for COVID-19

April 5, 2020News, Recombinant Antibody R&DClinical Development, SARS-CoV-2, therapeutic antibodybiorab

The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…

Posts navigation

  • 1
  • 2
  • 3
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer
  • A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection
  • Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections
  • Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer
  • Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News